机构:[1]Capital Med Univ, Beijing Tiantan Hosp, Dept Neurol, Beijing, Peoples R China;重点科室诊疗科室神经病学中心首都医科大学附属天坛医院[2]China Natl Clin Res Ctr Neurol Dis, Beijing, Peoples R China;国家神经系统疾病临床医学研究中心国家神经系统疾病临床医学研究中心首都医科大学附属天坛医院[3]Chinese Ctr Dis Control & Prevent, Natl Ctr Chron & Noncommunicable Dis Control & Pr, Beijing, Peoples R China;[4]Chinese Ctr Dis Control & Prevent, Beijing, Peoples R China;[5]Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA;[6]Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA;[7]Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Div Neurol, Shatin, Hong Kong, Peoples R China
Objectives: To investigate the prevalence, knowledge, and treatment of TIA in a Chinese adult population. Methods: We conducted a complex, multistage, probability sampling-designed, cross-sectional, nationwide survey of 98,658 Chinese adults in 2010. Possible TIA cases were first identified by symptoms recall or self-reported history of TIA through face-to-face interviews, and the final diagnosis was then made by expert neurologists through phone interviews or record review. Results: The age-standardized prevalence of TIA was 2.27%. Clinically, only 16.0% of the participants were diagnosed before the study. The prevalence of TIA was higher in women and in patients who were older, had less education, were current smokers, lived in rural or undeveloped areas, and had a history of stroke, hypertension, myocardial infarction, dyslipidemia, or diabetes. Based on the survey responses, approximately 3.08% of Chinese adults had knowledge of TIA. Among patients with TIA, only 5.02% received treatment and 4.07% received guideline-recommended therapy. Conclusions: TIA is prevalent and an estimated 23.9 million people in China may have experienced a TIA. Public knowledge on TIA is very limited. TIA appears to be largely undiagnosed and untreated in China. There is an urgent need to develop strategies to improve the identification and appropriate management of TIA.
基金:
Ministry of Science and Technology of the People's Republic of ChinaMinistry of Science and Technology, China [2007BAI24B03, 2011BAI08B02, 2013BAI09B03]; Beijing Institute for Brain Disorders [BIBD-PXM2013_014226_07_000084]; Sanofi (China)Sanofi-Aventis
第一作者机构:[1]Capital Med Univ, Beijing Tiantan Hosp, Dept Neurol, Beijing, Peoples R China;[2]China Natl Clin Res Ctr Neurol Dis, Beijing, Peoples R China;
通讯作者:
通讯机构:[1]Capital Med Univ, Beijing Tiantan Hosp, Dept Neurol, Beijing, Peoples R China;[2]China Natl Clin Res Ctr Neurol Dis, Beijing, Peoples R China;
推荐引用方式(GB/T 7714):
Wang Yilong,Zhao Xingquan,Jiang Yong,et al.Prevalence, knowledge, and treatment of transient ischemic attacks in China[J].NEUROLOGY.2015,84(23):2354-2361.doi:10.1212/WNL.0000000000001665.
APA:
Wang, Yilong,Zhao, Xingquan,Jiang, Yong,Li, Hao,Wang, Limin...&Wang, Yongjun.(2015).Prevalence, knowledge, and treatment of transient ischemic attacks in China.NEUROLOGY,84,(23)
MLA:
Wang, Yilong,et al."Prevalence, knowledge, and treatment of transient ischemic attacks in China".NEUROLOGY 84..23(2015):2354-2361